Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
|Shares Outstanding||EPS||-1.66||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-8.67|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-20.57%||ROE||-21.41%||ROI|
|Current Ratio||25.65||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||10 K||Cash From Investing Activities||-20.47 M||Cash From Operating Activities||-7.63 M||Gross Profit|
|Net Profit||-7.86 M||Operating Profit||-7.87 M||Total Assets||96.87 M||Total Current Assets||90.31 M|
|Total Current Liabilities||3.52 M||Total Debt||Total Liabilities||3.77 M||Total Revenue|
|High 52 week||6.75||Low 52 week||2.52||Last close||2.6||Last change||1.96%|
|RSI||26.01||Average true range||0.26||Beta||1.45||Volume||180.6 K|
|Simple moving average 20 days||-15.61%||Simple moving average 50 days||-28.08%||Simple moving average 200 days||-46.18%|
|Performance Week||-4.41%||Performance Month||-36.59%||Performance Quart||-39.53%||Performance Half||-59.25%|
|Performance Year||-59.06%||Performance Year-to-date||-42.22%||Volatility daily||4.51%||Volatility weekly||10.1%|
|Volatility monthly||20.69%||Volatility yearly||71.67%||Relative Volume||2060.39%||Average Volume||340.44 K|
|New High||New Low|
2020-05-27 07:01:10 | Calithera to Present at the Jefferies Virtual Healthcare Conference
2020-05-18 11:30:03 | Has Calithera Biosciences CALA Outpaced Other Medical Stocks This Year?
2020-05-13 09:15:01 | Is Calithera Biosciences CALA Stock a Solid Choice Right Now?
2020-05-11 12:00:04 | What Makes Calithera CALA a New Buy Stock
2020-05-08 16:27:35 | Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT
2020-05-08 13:01:54 | Calithera Biosciences Inc CALA Q1 2020 Earnings Call Transcript
2020-05-07 16:05:10 | Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights
2020-04-16 00:18:32 | Calithera Biosciences, Inc. Prices Public Offering of 5,000,000 shares of Common Stock
2020-04-14 08:48:12 | Calithera CALA Soars: Stock Adds 9.4% in Session
2020-04-14 07:00:10 | Calithera Biosciences Provides Update on Business Operations
2020-04-13 11:14:00 | How to Play Speculative Calithera Biosciences
2020-04-07 09:30:15 | Billionaire Steven Cohen Picks up These 2 Stocks on the Dip
2020-03-28 09:09:40 | Have Insiders Been Buying Calithera Biosciences, Inc. NASDAQ:CALA Shares?
2020-03-12 03:00:11 | Edited Transcript of CALA earnings conference call or presentation 11-Mar-20 9:00pm GMT
2020-03-11 15:00:00 | Calithera Biosciences, Inc. to Host Earnings Call
2020-02-19 07:05:10 | Calithera to Participate in the 9th Annual SVB Leerink Global Healthcare Conference
2020-01-30 09:38:05 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Paid Enough Relative To Peers?
2019-12-13 14:46:42 | Hedge Funds Are Dumping Calithera Biosciences Inc CALA
2019-12-02 11:38:03 | Imagine Owning Calithera Biosciences NASDAQ:CALA While The Price Tanked 64%
2019-11-23 08:36:35 | Edited Transcript of CALA earnings conference call or presentation 12-Nov-19 10:00pm GMT
2019-11-12 16:06:00 | Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-19 09:23:18 | Read This Before Selling Calithera Biosciences, Inc. NASDAQ:CALA Shares
2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study
2019-09-27 09:28:01 | Calithera Biosciences Enters Oversold Territory
2019-09-26 12:00:04 | Implied Volatility Surging for Calithera CALA Stock Options
2019-09-25 08:05:00 | Calithera to Present at the 2019 Cantor Global Healthcare Conference
2019-09-19 10:06:40 | Calithera Biosciences, Inc. NASDAQ:CALA: Is It Growing Too Fast?
2019-08-23 09:11:52 | Is Calithera Biosciences, Inc.'s NASDAQ:CALA CEO Pay Justified?